Who are PNA's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Stannous Fluoride Dentifrice, Clindamycin and BPO 5% gel, Benzalkonium Chloride-Benzocaine Topical, Neutrogena Rapid Clear®, Sensodyne Sensitivity & Gum, PerioChip ®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pna.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

PNA — Competitive Intelligence Brief

PNA (PNA) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimicrobial peptide. Area: Infectious diseases.

marketed Antimicrobial peptide Bacterial cell membranes Infectious diseases Small molecule Live · refreshed every 30 min

Target snapshot

PNA (PNA) — Guangzhou Yipinhong Pharmaceutical CO.,LTD. PNA is a type of antimicrobial peptide that works by disrupting bacterial cell membranes.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
PNA TARGET	PNA	Guangzhou Yipinhong Pharmaceutical CO.,LTD	marketed	Antimicrobial peptide	Bacterial cell membranes
Stannous Fluoride Dentifrice	Stannous Fluoride Dentifrice	Procter and Gamble	marketed	Topical fluoride dentifrice	Tooth enamel (hydroxyapatite); bacterial cell membranes
Clindamycin and BPO 5% gel	Clindamycin and BPO 5% gel	Stiefel, a GSK Company	marketed	Topical antibiotic combination with keratolytic agent	Bacterial 50S ribosome (clindamycin); oxidative damage to bacterial cell membranes (BPO)
Benzalkonium Chloride-Benzocaine Topical	Benzalkonium Chloride-Benzocaine Topical	Medice Arzneimittel Pütter GmbH & Co KG	marketed	Topical antimicrobial-anesthetic combination	Bacterial cell membranes (benzalkonium); sodium channels (benzocaine)
Neutrogena Rapid Clear®	Neutrogena Rapid Clear®	GlaxoSmithKline	marketed	Topical antimicrobial/keratolytic agent	Cutibacterium acnes (bacterial cell membranes and proteins)
Sensodyne Sensitivity & Gum	Sensodyne Sensitivity & Gum	HALEON	marketed	Desensitizing toothpaste with antimicrobial and anti-inflammatory agents	Sensory nerve fibers (potassium nitrate); bacterial cell membranes and gum tissue (stannous compounds)
PerioChip ®	PerioChip ®	Dexcel Pharma Technologies Ltd.	marketed	Local antimicrobial agent	Bacterial cell membranes (chlorhexidine non-specific antimicrobial)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimicrobial peptide class)

Abeona Therapeutics, Inc · 1 drug in this class
Dipexium Pharmaceuticals, Inc. · 1 drug in this class
Guangzhou Yipinhong Pharmaceutical CO.,LTD · 1 drug in this class
Maruho Co., Ltd. · 1 drug in this class
Tufts Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PNA — Competitive Intelligence Brief. https://druglandscape.com/ci/pna. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab